The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.
Trine Zeeberg Iversen
No relevant relationships to disclose
Lotte Engell-Noerregaard
No relevant relationships to disclose
Eva Ellebaek
No relevant relationships to disclose
Rikke Andersen
No relevant relationships to disclose
Stine Kiaer Larsen
No relevant relationships to disclose
Jon Bjoern
No relevant relationships to disclose
Merete Jonassen
No relevant relationships to disclose
Hubert Kalbacher
No relevant relationships to disclose
Claus Zeyher
No relevant relationships to disclose
Cecile Gouttefangeas
No relevant relationships to disclose
Inger Birthe Moerk Thomsen
No relevant relationships to disclose
Bente Holm
No relevant relationships to disclose
Anders Mellemgaard
No relevant relationships to disclose
Per thor Straten
No relevant relationships to disclose
Mads Hald Andersen
No relevant relationships to disclose
Inge Marie Svane
No relevant relationships to disclose